However, previous and current clinical trials in T1D utilize Treg products that lack the target recognition critical for Tregs to function at intended tissue sites and do not provide IL-2 support within an IL-2–deficient pancreatic environment. This evidence concerns the gene IL2 and type 1 diabetes mellitus.